Bayer and GlaxoSmithKline Urge Baycol MDL Court to Expedite Discovery

MINNEAPOLIS - Bayer and GlaxoSmithKline proposed on Dec. 12 that the U.S. District Court for the District of Minnesota 'wrap-up' the Baycol MDL by continuing discovery and dismissing cases 'devoid of evidentiary support on injury and causation.' In re Baycol Products Litigation. MDL NO. 1431. Case No. 0:01-md-01431 (D. Minn.)

In their proposal, Bayer and GlaxoSmithKline said case-specific discovery should be completed to make cases trial-ready prior to remand. The filing of generic Daubert motions should be required and pre-remand mediation of all cases should be ordered, the companies assert.

Since the Baycol (ceivastatin) MDL was created in December 2001, …